# OnCo record paper-elm-2-odronextamab-follicular-ann-oncol-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-elm-2-odronextamab-follicular-ann-oncol-2024" ;
  schema:name "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma"@en ;
  schema:alternateName "ELM-2"@en, "Kim 2024"@en, "Odronextamab in follicular lymphoma"@en ;
  schema:description "A two-headed antibody given alone put nearly three quarters of people with repeatedly relapsed follicular lymphoma into complete remission, lasting a median of two years."@en ;
  schema:url <https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2024.08.2239>, <https://pubmed.ncbi.nlm.nih.gov/39147364/>, <https://europepmc.org/article/MED/39147364> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2024.08.2239> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Kim TM, Taszner M, Novelli S, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/odronextamab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/> ;
  onco:trials <https://onco.cc/trials/nct03888105/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .